Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annovis Bio, Inc.ANVS · Entity 7001 | Director | September 10, 2025 | November 12, 2025 |
| NAVIDEA BIOPHARMACEUTICALS, INC.NAVB · Entity 107761 | Director | June 30, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annovis Bio, Inc.
Report date September 10, 2025 · Filed November 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,709 |
Reported balance
After 2025-09-10 transaction · row 1
1 source rowRow 1 · 2025-09-10 · Exercise / conversion · Acquired 7,142 · Balance 13,709 |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2025-09-18 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-09-10 · Exercise / conversion · Disposed 7,142 · Balance 0 |
NAVIDEA BIOPHARMACEUTICALS, INC.
Report date June 30, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,519 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 3,969 · Balance 16,519 F1: Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of quarterly non-employee director fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of quarterly non-employee director fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2025 Filed Nov 12, 2025 14:17 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionOption · Derivative | 7,142 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-25-109904 · tm2527472-1_4seq1.xml · derivative · entry 2 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,142 shares Expires 2025-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2025 Filed Nov 12, 2025 14:17 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionCommon Stock | 7,142 | $0.14 | $999.88 |
DisclosureSEC source: 0001104659-25-109904 · tm2527472-1_4seq1.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 19:27 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 1,000 | $6.07 | $6,070.00 |
DisclosureSEC source: 0001104659-23-120299 · tm2331305-1_4seq1.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,567 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:14 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-120749 · tm2331305-7_4aseq1.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,567 F1 · kind: This amendment is being filed solely to reverse the previously reported purchase on the original form 4 filed on November 21, 2023 (the "Original Form 4"). Such purchase was rescinded by the registrant and the reporting person on November 22, 2023. Read SEC document |
| November 17, 2023 Filed Jul 3, 2024 21:15 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 26,200 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-24-077831 · tm2417696-1_4seq1.xml · derivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,200 Underlying: Common Stock · 26,200 shares Expires 2033-11-17 F1 · security: On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. F2 · derivative.exercise_date: The stock option shall vest immediately upon grant date. Read SEC document |
| April 07, 2023 Filed Apr 12, 2023 01:11 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 500 | $12.61 | $6,305.00 |
DisclosureSEC source: 0001104659-23-044208 · tm2312464-5_4seq1.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,567 Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 22:37 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 5,967 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0001104659-23-005475 · tm234043-1_4seq1.xml · derivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,967 Underlying: Common Stock · 5,967 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option shall vest in eight consecutive equal quarterly installments each on the 18th day of April, July, October and January of each year, commencing April 18, 2023, and continuing through January 18, 2025. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:40 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0001104659-22-001637 · tm221949-1_4seq1.xml · derivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: The stock option shall vest in eight consecutive quarterly installments of 1,000 shares each on the 3rd day of April, July, October and January of each year, commencing April 3, 2022, and continuing through January 3, 2024. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 20:03 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 181 | $27.66 | $5,006.46 |
DisclosureSEC source: 0001415889-21-004864 · form4-10132021_011056.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 22:25 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $102.85 | $0.00 |
DisclosureSEC source: 0001104659-21-090741 · tm2121908-1_4seq1.xml · derivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2031-07-07 F1 · derivative.exercise_date: The stock option shall vest in eight substantially equal quarterly installments beginning October 7, 2021, provided that the reporting person continues to serve as a director of the issuer on the applicable vesting date. Read SEC document |
| June 30, 2021 Filed Jul 7, 2021 17:44 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 3,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-016596 · rdgdoc.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,519 F1 · shares: Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of quarterly non-employee director fees. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 16:35 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 2,500 | $0.00 Strike: $2.28 | $2.50 |
DisclosureSEC source: 0001437749-21-000725 · rdgdoc.xml · derivative · entry 2 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-01-13 Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 16:35 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 2,500 | $0.00 | $2.50 |
DisclosureSEC source: 0001437749-21-000725 · rdgdoc.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,550 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:32 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001104659-20-081248 · a4.xml · derivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-01 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:09 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 2,500 | $0.00 Strike: $1.06 | $2.50 |
DisclosureSEC source: 0001437749-20-002027 · rdgdoc.xml · derivative · entry 2 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2030-02-06 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:09 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 2,500 | $0.00 | $2.50 |
DisclosureSEC source: 0001437749-20-002027 · rdgdoc.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,050 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the on-year anniversary of the date of grant. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:04 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionConvertible Note · Derivative | 1,117 | $4.80 | $5,361.60 |
DisclosureSEC source: 0001104659-20-010940 · a4.xml · derivative · entry 5 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F3 · shares: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F3 · derivative.exercise_date: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F3 · derivative.expiration_date: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:04 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionSeries A-1 Preferred Stock · Derivative | 5,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-010940 · a4.xml · derivative · entry 4 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.expiration_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:04 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 1,117 | $4.80 | $5,361.60 |
DisclosureSEC source: 0001104659-20-010940 · a4.xml · nonDerivative · entry 3 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:04 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 3,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-010940 · a4.xml · nonDerivative · entry 2 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:04 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 800 | $6.00 | $4,800.00 |
DisclosureSEC source: 0001104659-20-010940 · a4.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · shares: The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis"). Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:06 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 2,550 | $1.90 | $4,855.20 |
DisclosureSEC source: 0001437749-19-010057 · rdgdoc.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,550 Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 16:10 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.25 | $50.00 |
DisclosureSEC source: 0001437749-19-002329 · rdgdoc.xml · derivative · entry 2 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-07 Read SEC document |
| February 07, 2019 Filed Feb 12, 2019 16:10 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-19-002329 · rdgdoc.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 10:43 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.75 | $50.00 |
DisclosureSEC source: 0001437749-18-004830 · rdgdoc.xml · derivative · entry 2 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-15 Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 10:43 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-18-004830 · rdgdoc.xml · nonDerivative · entry 1 Bruck Claudine · CIK 0001733680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.